Racing Force Group and Bahrain International Circuit Announce Completion of Bell Racing Helmets Factory Extension and Groundbreaking for New OMP Production Facility

4.11.2024 11:05:00 CET | ACCESS Newswire | Press release

Share
  • Major expansion of Racing Force Group production facilities located at The Home of Motorsport in the Middle East.

  • New OMP factory reflects Racing Force Group's long-term commitment to Bahrain as leader in motorsports safety equipment

MANAMA, BAHRAIN / ACCESSWIRE / November 4, 2024 / Racing Force Group, the leading supplier of motorsports safety products and Bahrain International Circuit (BIC), "The Home of Motorsport in the Middle East", announced today the completion of the extension of the Bell Racing Helmets factory at BIC, together with the groundbreaking for a new production hub for OMP located adjacent to the Bell Racing Helmets facility. Bell Racing Helmets and OMP are both part of Racing Force Group and these latest developments reflect the long-term commitment to Bahrain of a notable motorsport company.

Racing Force is the leading motorsports safety products group with the most advanced and comprehensive range of protection and performance products used worldwide by top professionals, amateur drivers, race teams and car manufacturers sold under brands such as Bell Racing Helmets, OMP, Zeronoise and Racing Spirit. Products under the Group's brands can be found in all world championships of car and kart racing, contributing to several victories and titles each year.

The completion of the Bell Racing Helmets extension has enabled the company to double its production capacity, with a facility that now covers 12,000 sqm. The factory produces a racing helmets range developed for countless racing disciplines including 70% of drivers on the FIA Formula 1 World Championship grid, as well as the collectible Bell Mini Helmets which replicate in 1:2 scale the models used by the stars of global motorsport.

Meanwhile, construction has now commenced on a new factory for OMP, a leading designer and manufacturer of racewear, car parts and accessories to provide safety in motorsport under the Racing Force Group. The new 15,000 sqm facility, located adjacent to the existing one at BIC, will enable the company to produce a selection of its key motorsport safety products at the new factory.

Racing Force Group has recently completed a capital increase, which has allowed Bahrain Mumtalakat Holding Company ("Mumtalakat") to become a strategic investor in the Group through a fully owned subsidiary. This investment aims to meet the rising global demand for motorsports safety products and will support the development of the new OMP facility, further enhancing the Group's position as a leader in safety systems for motorsports.

Sheikh Salman bin Isa Al Khalifa, Chief Executive of Bahrain International Circuit, said:

"The completion of the Bell Racing Helmets factory extension and the start of work on the new OMP facility are two further milestones in the fruitful partnership that we enjoy with Racing Force Group. We are delighted to be able to support such historic and respected brands in global motorsport. Our partnership reflects BIC's position as the Home of Motorsport in the Middle East in its broadest sense and I thank all the entities in Bahrain that facilitate our endeavors, in particular Mumtalakat."

Stephane Cohen, Co-CEO of Racing Force Group and CEO of Racing Force Bahrain, commented:

"Since 2015, our partnership with Bahrain International Circuit has become increasingly close, ensuring us the best conditions and resources to confirm ourselves as the leading manufacturer of state-of-the-art motorsport helmets. The completion of the Sakhir factory extension is another key step in this highly successful alliance. Starting from Bell Racing Helmets, the link with the Bahrain International Circuit now includes the entire Racing Force Group, and following Mumtalakat's investment we can announce the beginning of construction of a second building in Sakhir. The facility will be a strategic asset for increasing the overall production of items in the OMP range, another benchmark brand in the racing industry. On behalf of the entire Group, I want to the thank once again the Bahrain International Circuit organization, CE Sheikh Salman bin Isa Al Khalifa, Mumtalakat, and the Bahrain local community for their constant support."

For more information, please contact:

Abdulelah Abdulla
Communications Department
Economic Development Board
Phone: +973-39798919
E-mail: internationalmedia@bahrainedb.com

SOURCE: Bahrain Economic Development Board



View the original press release on accesswire.com

Bahrain Economic Development Board

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades2.2.2026 15:00:00 CET | Press release

Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications. This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup. With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye